ÂÜÀòÂÒÂ×

Jay Fine is an accomplished leader in the pharmaceutical and biotechnology sectors, currently serving as President of Research and Development at EvolveImmune Therapeutics since May 2022 and as an Independent Board Director at OrphAI Therapeutics since January 2024. Fine's previous experience includes a significant tenure at Boehringer Ingelheim from September 2011 to April 2022, where responsibilities included Senior Vice President and Global Head of Immunology and Respiratory Diseases Research. Prior roles also encompass Research Director in Inflammation Biology at Roche Pharmaceuticals and various leadership positions at Schering-Plough from 1991 to 2009. Fine holds a PhD from the University of Rochester School of Medicine and Dentistry and a BS from Cornell University.